Which has the lower trailing P/E, ABUS or HSTM?

ABUS has the lower trailing P/E: ABUS trades at 5.74 and HSTM at 43.77. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ABUS or HSTM?

Over the past five years, ABUS grew revenue faster — ABUS at a 85.17% CAGR versus HSTM at 5.05%.

Does ABUS or HSTM pay a bigger dividend?

HSTM pays a dividend (0.43% yield), while ABUS has no payments in the available dividend history.

Is ABUS or HSTM more profitable?

ABUS runs the higher net margin — ABUS at 84.23% versus HSTM at 6.60%.

How have ABUS and HSTM total returns compared?

Over the past 10 years, ABUS delivered 2.93% and HSTM delivered 1.25% annualized total return. Past performance doesn't predict future results.

Arbutus Biopharma Corp (ABUS) vs HealthStream, Inc. (HSTM)

A side-by-side comparison of Arbutus Biopharma Corp and HealthStream, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ABUS

Arbutus Biopharma Corp

$885M

$4.48HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

HSTM

HealthStream, Inc.

$915M

$31.31HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ABUS vs HSTM

growth of $100 · dividends reinvested · last 10y

ABUS +45.9% (+3.9%/yr)HSTM +19.7% (+1.8%/yr)ABUS compounded faster over this window

ABUS HSTM

ABUS vs HSTM: by the numbers

•HSTM is the larger company ($915M vs $885M market cap).
•ABUS trades at the lower trailing earnings multiple (5.74 vs 43.77 P/E), one valuation lens rather than an overall verdict.
•ABUS converts more revenue to profit (84.23% vs 6.60% net margin).
•ABUS grew revenue faster over the past five years (85.17% vs 5.05% CAGR).
•HSTM pays a dividend (0.43% yield), while ABUS has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	ABUS	HSTM
P/E ratio	5.74	43.77
Forward P/E	6.05	42.43
PEG ratio	N/A	6.48
P/S ratio	4.87	2.85
P/B ratio	3.42	2.57
EV / EBITDA	5.90	12.55
FCF yield	N/A	5.34%

Profitability

Metric	ABUS	HSTM
Gross margin	99.98%	65.08%
Operating margin	-192.08%	8.04%
Net margin	84.23%	6.60%
ROE	59.16%	5.94%
ROIC	54.39%	4.96%

Dividends

Metric	ABUS	HSTM
Dividend yield	N/A	0.43%
Payout ratio	N/A	19.01%

Growth (annualized)

Metric	ABUS	HSTM
Revenue CAGR (5Y)	85.17%	5.05%
EPS CAGR (5Y)	N/A	6.75%
FCF CAGR (5Y)	N/A	2.33%
Total return CAGR (5Y)	2.19%	2.34%

Frequently asked

Which has the lower trailing P/E, ABUS or HSTM?: ABUS has the lower trailing P/E: ABUS trades at 5.74 and HSTM at 43.77. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ABUS or HSTM?: Over the past five years, ABUS grew revenue faster — ABUS at a 85.17% CAGR versus HSTM at 5.05%.
Does ABUS or HSTM pay a bigger dividend?: HSTM pays a dividend (0.43% yield), while ABUS has no payments in the available dividend history.
Is ABUS or HSTM more profitable?: ABUS runs the higher net margin — ABUS at 84.23% versus HSTM at 6.60%.
How have ABUS and HSTM total returns compared?: Over the past 10 years, ABUS delivered 2.93% and HSTM delivered 1.25% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ABUS analysis Full HSTM analysis Interactive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratio HealthStream P/E ratio HealthStream dividend yield Arbutus Biopharma ROE HealthStream ROE Arbutus Biopharma operating margin HealthStream operating margin Arbutus Biopharma revenue growth HealthStream revenue growth Arbutus Biopharma free cash flow HealthStream free cash flow

Arbutus Biopharma & HealthStream appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.